

1 R. Brent Wisner, Esq, (SBN: 276023)
2 rbwisner@wisnerbaum.com
3 Stephanie B. Sherman, Esq. (SBN: 338390)
4 ssherman@wisnerbaum.com
5 **WISNER BAUM, L.L.P**
6 11111 Santa Monica Boulevard, Suite 1750
7 Los Angeles, CA 90025
8 Telephone: (310) 207-3233
9 Facsimile: (310) 820-7444

10 *Attorneys for Plaintiff*

11 **UNITED STATES DISTRICT COURT**
12 **EASTERN DISTRICT OF CALIFORNIA**

13 CHINYERE HARRIS on behalf of herself, and
14 all others similarly situated, and the general
15 public,

16 Plaintiffs,

17 v.

18 GENOMMA LAB USA, INC and DOES 1 to
19 50, Inclusive,

20 Defendants.

Civil Action No.

21 **CLASS ACTION COMPLAINT**

22 **CONSUMER FRAUD, BREACH OF**
23 **EXPRESS & IMPLIED WARRANTIES,**
24 **AND UNJUST ENRICHMENT**

25 **DEMAND FOR JURY TRIAL**

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. THE PARTIES	5
III. JURISDICTION AND VENUE	6
IV. GENERAL ALLEGATIONS.....	6
A. DEFENDANT DID NOT COMPLY WITH FDA’S TESTING REQUIREMENTS BEFORE SELLING THE PRODUCTS TO THE PUBLIC	7
B. DEFENDANT KNEW OR SHOULD HAVE KNOWN THE BPO PRODUCTS DEGRADED TO BENZENE UNDER NORMAL USE, HANDLING, AND STORAGE.....	8
C. DEFENDANT KNEW OR SHOULD HAVE KNOWN BENZENE WAS FOUND IN OTHER CONSUMER PRODUCTS BUT DID NOT TEST THEIR BPO PRODUCTS	11
D. DEFENDANT IGNORED FDA’S BENZENE ALERT TO TEST BPO PRODUCTS	11
E. RECENT TESTING FOUND COMMON BPO PRODUCTS CONTAIN DANGEROUS LEVELS OF BENZENE IN EXCESS OF REGULATORY LIMITS.....	12
F. DEFENDANT EXPOSED PLAINTIFF, THE CLASS, AND THE PUBLIC TO BENZENE, A KNOWN HUMAN CARCINOGEN, WITHOUT THEIR KNOWLEDGE.....	17
G. DEFENDANT MARKETING ITSELF AS A COMPANY OF INTEGRITY BUT CONCEALED FROM CONSUMERS THEIR FAILURE TO TEST THE BPO PRODUCTS FOR SAFETY	20
H. DEFENDANT DID NOT WARN PLAINTIFF, THE CLASS, AND SUBCLASS THE BPO PRODUCTS WERE AT RISK OF BENZENE CONTAMINATION.....	21
I. DEFENDANT DIRECTLY MARKETING THE BPO PRODUCTS TO CHILDREN AND TEENAGERS	21
V. PUNITIVE DAMAGES ALLEGATIONS.....	22
VI. PLAINTIFF SPECIFIC ALLEGATIONS.....	23
VII. CLASS ACTION ALLEGATIONS.....	24
VIII. CAUSES OF ACTION.....	27

1	A.	VIOLETION OF CALIFORNIA’S UNFAIR COMPETITION LAW <i>Bus. & Prof. Code § 17200 et seq., on Behalf of the California Subclass</i>	27
2	B.	VIOLETION OF CALIFORNIA’S CONSUMER LEGAL REMEDIES ACT, <i>Cal. Civ. Code § 1750, et seq., on Behalf of the California Subclass</i>	30
3	C.	FALSE ADVERTISING UNDER VARIOUS STATE STATUTES, <i>on Behalf</i> <i>of the California, Hawaii and New York Subclasses</i>	32
4	D.	DECEPTIVE TRADE PRACTICES UNDER VARIOUS STATE STATUTES, <i>on</i> <i>Behalf of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts,</i> <i>Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington</i> <i>Subclasses</i>	34
5	E.	BREACH OF EXPRESS WARRANTY, <i>on Behalf of the Nationwide Class and on</i> <i>Behalf of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts,</i> <i>Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and</i> <i>Washington State Subclasses</i>	38
6	F.	BREACH OF IMPLIED EXPRESS WARRANTY, <i>on Behalf of the Nationwide</i> <i>Class and on Behalf of the California, Hawaii, Illinois, Maryland, Massachusetts,</i> <i>Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington</i> <i>Subclasses</i>	39
7	G.	UNJUST ENRICHMENT, <i>on Behalf of the Nationwide Class and on Behalf of</i> <i>the California, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York,</i> <i>Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses</i>	40
8	IX.	PRAYER FOR RELIEF	41
9	X.	DEMAND FOR JURY TRIAL	42

1 Plaintiff, CHINYERE HARRIS, on behalf of herself, the proposed Class and Subclasses
 2 (defined below), and the public, brings this Class Action Complaint (“Class Action”) against
 3 Defendant, alleging the following upon Plaintiff’s personal knowledge, or where Plaintiff lacks
 4 personal knowledge, upon information and belief, including the investigation of counsel.

5 **I. INTRODUCTION**

6 1. This is a consumer fraud Class Action to redress the economic harms caused by
 7 Defendant’s sale of benzoyl peroxide acne treatment drug products (“BPO Products” or “Products”)
 8 without warning consumers the BPO Products contained unsafe levels of the potent human carcinogen
 9 benzene, and that the BPO Products were at risk of degrading further into benzene under normal use,
 10 handling, and storage conditions.

11 2. The BPO Products are “drugs” used to treat acne vulgaris (“acne”), formulated with a
 12 chemical called benzoyl peroxide (“BPO”), along with other inactive ingredients, to make acne
 13 treatment creams, washes, scrubs, and bars. Before being sold to the public, the Products must be
 14 made in conformity with current good manufacturing practices and must conform to quality, safety,
 15 and purity specifications. Defendant’s BPO Products did not.

16 3. BPO Products should not contain benzene, nor degrade into benzene, except under
 17 extraordinary circumstances.¹ A drug is “adulterated” if it consists in whole or in part of any filthy,
 18 putrid, or decomposed substance, is impure, or mixed with another substance.² Under the FDA Act, it
 19 is a crime to introduce or deliver “into interstate commerce any food, drug, device, tobacco product, or
 20 cosmetic that is adulterated or misbranded.”³ If benzene is found in any on-market or post-market
 21 Product, the drug is unlawful and the drug manufacturer must contact the FDA to initiate a voluntary
 22 recall.⁴

23 4. Throughout this Complaint, references to federal law and FDA regulation are merely to
 24

25 ¹ Food and Drug Administration, *Q3C – Tables and List Guidance for Industry* (2017),
<https://www.fda.gov/media/71737/download>.

26 ² 21 U.S.C. § 351(a)(2011); *see also* § 351(b)-(d) (noting that a lack of purity or mixture with another
 substance also renders drug adulterated).

27 ³ 21 U.S.C. § 331(a)(2010).

28 ⁴ Food and Drug Administration. (Dec. 22, 2022). *FDA Alerts Drug Manufacturers to the Risk of
 Benzene in Certain Drugs*, [https://www.fda.gov/drugs/pharmaceutical-quality-resources/fda-alerts-
 drug-manufacturers-risk-benzene-contamination-certain drugs](https://www.fda.gov/drugs/pharmaceutical-quality-resources/fda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs) (last visited Feb. 9, 2024).

1 provide context and are not intended to raise a federal question of law. All claims alleged herein arise
2 out of violations of state law, which in no way conflict, interfere with, or impose obligations that are
3 materially different than those imposed by federal law.

4 5. The BPO Products marketed and sold by Defendant to Plaintiff, the Class, Subclasses,
5 and the public decomposed into benzene rendering them materially different than advertised, *i.e.*, by
6 containing unsafe levels of benzene. Benzene is a known human carcinogen. Studies dating to the
7 1800s have led to a consensus within the medical and scientific communities that benzene exposure,
8 even in low amounts, increases the risk of blood cancers and other adverse effects.

9 6. In 2023, Valisure, LLC,⁵ an independent, accredited laboratory that has developed
10 analytical methods to test drugs and consumer products for public safety, tested a representative
11 sample of BPO and non-BPO products and found the BPO Products had dangerous levels of benzene,
12 many multiple times higher than allowed in any regulated drug.⁶ Using industry standard gas
13 chromatography and detection by mass spectrometry (“GC-MS”) instrumentation, with selected ion
14 flow tube mass spectrometry (“SIFT-MS”) for detection of benzene released into the air around
15 certain BPO Products, the Products were incubated to temperatures common during consumer use,
16 handling, and storage and sampled for benzene.⁷ Levels as high as 1600 parts per million (ppm) were
17 found in common BPO Products.⁸ Unexpectedly, researchers found that benzene was released into

18 ⁵ Valisure is an independent third-party analytical laboratory that is accredited to International
19 Organization for Standardization (“ISO/IEC”) 17025:2017 standards for chemical testing (PJLA
20 Accreditation Number 94238). In response to rising concerns about drug shortages, generics, and
21 overseas manufacturing, Valisure developed and validated methods to test medications and consumer
22 products distributed in the United States. Valisure has tested a variety of drug and consumer
23 healthcare products for benzene including sunscreens, antiperspirants, body sprays, hand sanitizers,
24 and dry shampoos for benzene. Valisure’s testing results submitted to the FDA in its Citizen’s
25 Petitions, were widely publicized in the media leading to numerous recalls of contaminated consumer
26 products. *See* Valisure Citizen’s Petition on Benzoyl Peroxide (March 4, 2024), pp. 6-7, *see also*
27 Valisure Detects Benzene in Sunscreen, [https://www.valisure.com/valisure-newsroom/valisure-](https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-sunscreen)
28 [detects-benzene-in-sunscreen](https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-sunscreen); Bruce Y. Lee, Forbes, FDA: P&G Recalls Antiperspirant Sprays Due
To Cancer Risk Of Benzene (Nov. 24, 2021), [https://www.forbes.com/sites/brucelee/2021/11/24/fda-](https://www.forbes.com/sites/brucelee/2021/11/24/fda-pg-recalls-antiperspirants-body-sprays-due-to-cancer-risk-of-benzene/?sh=69cf13c24f32)
pg-recalls-antiperspirants-body-sprays-due-to-cancer-risk-of-benzene/?sh=69cf13c24f32; *see also*
Santee LaMotte, CNN, Antiperspirant recall: What the finding of a cancer-causing chemical means
for you (Dec. 1, 2021), [https://www.cnn.com/2021/12/01/health/deodorants-antiperspirants-recall-](https://www.cnn.com/2021/12/01/health/deodorants-antiperspirants-recall-benzene-explainer-wellness/index.html)
benzene-explainer-wellness/index.html.

⁶ Valisure FDA Citizen’s Petition on Benzoyl Peroxide (March 6, 2024).

⁷ *Id.*

⁸ *Id.* at 17.

the surrounding air even when the BPO Products’ packaging was closed raising concern for even more inhalation exposures—a particularly pernicious form of exposure to benzene.⁹ For the non-BPO products tested, benzene was not present, or at trace levels below 2 ppm.¹⁰ Valisure filed a FDA Citizen’s Petition on March 5, 2024 demanding an immediate recall of all BPO Products.¹¹ The Petition is pending.¹²

7. The high levels of benzene found led Valisure to conduct a stability study on a diverse market sweep of BPO Products and formulations. Valisure’s results show that on-market BPO Products can form over 800 times the conditionally restricted FDA concentration limit of 2 ppm for benzene, and the evidence suggests this problem applies broadly to BPO Products currently on the market.¹³ Valisure concluded that on-market BPO Products appear to be fundamentally unstable and form unacceptably high levels of benzene when handled or stored at temperatures the Products will be exposed to during expected use and handling by consumers.¹⁴

8. Although the BPO Products have been found to have benzene, Defendant never listed benzene among the ingredients, or anywhere on the Products’ labels, containers, advertising or on Defendant’s websites. Defendant warned no one the Products had benzene or were at risk of benzene contamination.

9. Defendant knew or should have known the BPO Products contain and/or degraded into benzene when exposed to expected consumer use, handling, and storage conditions. BPO is known, within the scientific community (but not among consumers) to degrade into benzene according to the

⁹ *Id.* at 23.

¹⁰ *Id.* at 15 (“76 non-BPO products had no detectable benzene or values below 0.1ppm. 6 non-BPO products contained traces of benzene below 2 ppm, which could be due to various inactive ingredients used in consumer products that have been theorized to contain trace benzene”); *see also* Valisure, LLC, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide> (last visited March 6, 2024).


¹¹ Valisure BPO Citizen’s Petition (March 5, 2024).

¹² Valisure’s Petition was still pending as of this Class Action’s filing.

¹³ Valisure, LLC, (March 6, 2024), *Valisure Discovers Benzoyl Acne Treatment Products are Unstable and Form Benzene*, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide> (last visited March 6, 2024).

¹⁴ *Id.*

mechanism below:¹⁵



10. Defendant misled Plaintiff, the Class, the Subclasses, and the public by representing the BPO Products only had the ingredients listed, and not benzene. Defendant misled Plaintiff, the Class, the Subclasses, and the public by representing the BPO Products were safe while concealing material health and safety information known to them, *e.g.*, the BPO Products degraded to benzene, or were contaminated with benzene. Defendant misled Plaintiff, the Class, the Subclasses, and the public by giving the BPO Products long expiration dates of 2-3 years, affirming to consumers the BPO Products were safe for use for years when Defendant knew or should have known the BPO Products degraded much sooner to benzene.

11. Defendant's statements and omissions of material health and safety information unreasonably placed Plaintiff, the Class, the Subclasses, and the public at risk of exposure to benzene without their knowledge and consent. Defendant's statements to Plaintiff, the Class, the Subclasses, and the public about the Products were false, misleading, unsubstantiated, and blatantly deceptive.

12. As a result of the Defendant's misconduct and consumer deception, the Plaintiff, the Class, the Subclasses, and the public were economically harmed, as they purchased a product that they

¹⁵ The disposition of benzoyl peroxide to form benzene. Benzoyl peroxide is known to thermally decompose to form two molecules of benzoyloxy radicals that can further decompose to benzoic acid or phenyl radicals with liberation of carbon dioxide. The phenyl radicals can then produce benzene. See Shang-Hao Liu, et al, *Thermal hazard evaluation of the autocatalytic reaction of benzoyl peroxide using DSC and TAM III*, THERMOCHIMICA ACTA, Volume 605, Pages 68-76, (2015), ISSN 0040-603, <https://www.sciencedirect.com/science/article/pii/S004060311500057X>.

1 otherwise would have never purchased. They were also physically harmed by being exposed to a
2 known human carcinogen.

3 13. This Class Action is necessary to redress the economic harms caused to Plaintiff, the
4 Class, and the Subclass members who bought the Products believing them to be safe and only
5 containing the ingredients on the BPO Products' labels, containers, in advertising, and on Defendant's
6 websites. This Class Action is further necessary to expose Defendant's ongoing consumer fraud and to
7 enjoin Defendant from continuing their misconduct and deception to protect the public.

8 14. Plaintiff brings this Class Action individually, and on behalf of those similarly situated,
9 and seeks to represent a National Class of consumers and State Subclasses of consumers from
10 California, Connecticut, Hawaii, Illinois, Maryland, Missouri, Massachusetts, Nevada, New York,
11 Ohio, Pennsylvania, Rhode Island, and Washington (defined *infra*). Plaintiff seeks damages,
12 reasonable attorneys' fees and costs, interest, restitution, other equitable relief, including an injunction
13 and disgorgement of all benefits and profits Defendant received from misconduct.

14 **II. THE PARTIES**

15 15. Plaintiff Chinyere Harris is a California resident, located in Fresno County, who bought
16 BPO Products including Asepxia Acne Spot Treatment Cream for Pimples and Blackheads from July
17 2022 to November 2023. Plaintiff has suffered economic damages and a result of Defendant's
18 violations of the state laws alleged herein. Plaintiff would never have purchased Defendant's BPO
19 Products had Defendant warned about the presence of benzene or that the Products could degrade into
20 benzene.

21 16. Defendant Genomma Lab USA Inc. ("Genomma") is a citizen of Texas with its
22 principal place of business in Houston, Texas. Genomma's BPO Product is Asepxia Acne Spot
23 Treatment Cream. At all relevant times, Genomma conducted business and derived substantial
24 revenue from its manufacturing, advertising, marketing, distributing, and selling of the BPO Products
25 within the State of California and in this District.

26 17. Defendant and its agents promoted, marketed, and sold the Products in California and in
27 this District. The unfair, unlawful, deceptive, and misleading advertising and labeling of the Products
28 were prepared and/or approved by Defendant and its agents and were disseminated by Defendant and

its agents through statements, labeling, and advertising containing the misrepresentations alleged and disseminated uniformly to Plaintiff and the Subclass members through Defendant's advertising, packaging, containers, and via its websites and social media.

III. JURISDICTION AND VENUE

18. This Court has jurisdiction over this matter because the amount in controversy exceeds \$5 million satisfying 28 U.S.C. § 1332(d)(2) for subject matter jurisdiction. This Court has supplemental jurisdiction over any state law claims under 28 U.S.C. § 1367.

19. Venue is proper in the Central District of California under 28 U.S.C. § 1391(b) because a substantial part of the events or omissions giving rise to the claims occurred in this District.

20. This Court has personal jurisdiction over the Defendant because Defendant transacts business in California, including in this District, has substantial aggregate contacts with the State of California and in this District, engaged in misconduct that has and had a direct, substantial, reasonably foreseeable, and intended effect of injuring people in California and in this District, and Defendant purposely availed itself of the benefits of doing business in California, and in this District. Plaintiff's claim arises out of and relates to the Defendant's actions and contacts with the State of California.

21. To the extent applicable, the Court also has pendant personal jurisdiction over claims alleged against Defendant that involve the same common nucleus of facts and actions that give rise to Plaintiff's claims that otherwise have proper personal jurisdiction within this Court.

IV. GENERAL ALLEGATIONS

22. Fifty million Americans suffer from acne annually.¹⁶ Acne is the most common skin condition in the United States with a prevalence among adolescents of almost 95 percent.¹⁷ Acne can begin as early as age seven and, for some, can persist through adulthood and into ages 50s and 60s.¹⁸ Millions of acne sufferers seek treatment every year making it a billion-dollar industry and a key business segment for Defendant.

23. Defendant is one of the leading pharmaceutical and personal care products companies in

¹⁶ American Association of Dermatology, <https://www.aad.org/media> (visited October 24, 2023).

¹⁷ JL Burton et al., *The prevalence of acne vulgaris in adolescence*, BR J

DERMATOL,(1971);85(2):119–126.

¹⁸ *Id.*

Mexico with an increasing international presence. Defendant develops, sells, and markets a broad range of premium brand end products, including BPO Products, many of which are leaders in their categories.¹⁹ Defendant's BPO Products are widely marketed, available, sold, and used by children, teenagers, and adults throughout the United States and the world. The acne treatment industry is a highly competitive billion-dollar market. To remain relevant and top of mind, Defendant spends millions of dollars every year promoting the Asepxia BPO Products directly to consumers, including teenagers, through social media, blogs, and onsite advertisements. Innovation, sustainability, and integrity are among Defendant's publicly stated core values its markets to attract consumers such as Plaintiff, and the Class and Subclass members.²⁰

A. DEFENDANT DID NOT COMPLY WITH FDA'S TESTING REQUIREMENTS BEFORE SELLING THE PRODUCTS TO THE PUBLIC

24. Despite Defendant's public affirmations of integrity, Defendant did not adequately test their BPO Products before selling them to the public. Defendant's BPO Products are "drugs" regulated by the FDA. As with any regulated drug, Defendant must follow current good manufacturing practices ("CGMPs"), have scientifically sound specifications, and must have test procedures and processes to ensure the drug's components (active and inactive ingredients), and finished products are safe. Both raw ingredient materials and finished batches must be tested before released to the public to confirm they meet specifications for identity, strength, quality, and purity.²¹ If testing results of the raw materials or finished product do not conform with the specifications, the product cannot be sold to the public. Defendant must also re-test any Products subject to deterioration.²² Any Products not made in conformity with the CMGPs is considered "adulterated" under 501(a)(2)(B) of the Food, Drug, and Cosmetic Act.²³

¹⁹ Genomma Lab, *About Us*, <https://mygenommalab.com/pages/about-us> (last visited November 6, 2023).

²⁰ *Id.*

²¹ 21 C.F.R. § 211.84 (1978); *see also* 21 C.F.R. § 211.160 (1978).

²² 21 C.F.R. § 211.160(b)(1)(1978).

²³ 21 C.F.R. § 225.1 (1976). Under 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act a drug is considered "adulterated" (poorer in quality by adding another substance) if the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with CGMP; *see also* Food and Drug

25. Defendant must also do stability testing to understand the “shelf life” of the Products and to assign an expiration date. It is well known that certain chemical ingredients can degrade or change because of environmental, and storage conditions such as light, moisture, temperature, and humidity, or because of the passage of time. The stability testing should cover all expected distributor and consumer storage, handling, and use conditions and must be done using “reliable, meaningful, and specific test methods.”²⁴ If stability testing finds a drug product is not stable under expected storage or use conditions, degrades, or create toxic byproducts, the product cannot be sold to the public.

26. The CGMPs and stability test requirements are there to ensure drug products are safe for public use. These are the minimum requirements. Because the drug manufacturers are largely self-regulated, the FDA must rely on drug manufacturers, the public, and concerned citizens to report unsafe drugs. The FDA cannot force a drug manufacturer to recall a contaminated drug.²⁵

B. DEFENDANT KNEW OR SHOULD HAVE KNOWN THE BPO PRODUCTS DEGRADED TO BENZENE UNDER NORMAL USE, HANDLING, AND STORAGE

27. Defendant knew or should have known the BPO Products degrade to benzene when exposed to heat. Defendant knew that, because of the chemical nature of the active and inactive ingredients, including BPO, the BPO Products were not stable and would degrade when exposed normal and expected use, handling, and storage conditions.

28. It is well known that BPO degrades to benzene when exposed to heat over time. This process was first reported in the scientific literature as early as 1936.²⁶ BPO degrades into benzene according to the mechanism below.²⁷


Administration, *Facts About the Current Good Manufacturing Practices (CGMP)*; <https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmp> (last visited Feb. 11, 2024).

²⁴ 21 CFR 211.166.

²⁵ Food and Drug Administration, *Facts About the Current Good Manufacturing Practices (CGMP)*; <https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmp> (last visited Feb. 11, 2024).

²⁶ H. Erlenmeyer and W. Schoenauer, *Über die thermische Zersetzung von Di-acyl-peroxyden*, HELV. CHIM. ACTA, 19, 338 (1936), <https://onlinelibrary.wiley.com/doi/10.1002/hlca.19360190153> (last visited Feb. 5, 2024).

²⁷ Benzoyl peroxide is known to thermally decompose to form two molecules of benzoyloxy radicals that can further decompose to benzoic acid or phenyl radicals with liberation of carbon dioxide. The



29. The degradation of BPO to benzene was known or should have been known to the Defendant, who promote themselves as expending substantial sums of money and resources to science and research. Defendant marketed themselves as mass merchandisers of quality drug and healthcare products. Defendant employed high-level scientists, chemists, and researchers to formulate and/or decide which drug products it will privately label and sell for public use. Defendant with these resources and expertise were aware of the well-known chemical processes that degrade their BPO Products into benzene when exposed to common use temperatures and conditions.

30. Defendant further knew or should have known that specific ingredients derived from hydrocarbons increased the risk the BPO Products would yield benzene.²⁸ At-risk ingredients include carbomers, mineral spirits, and other petroleum derived substances. These ingredients are red flags for risk of benzene contamination. The FDA published guidance in 2022 urging the industry to reformulate drug products at risk of benzene contamination.²⁹ The FDA's alert highlighted ingredients made from hydrocarbons, including carbomers (thickening agents), urging drug manufacturers to test products containing them for benzene contamination.³⁰ Many of the Defendant's Products contain hydrocarbons and carbomers but none have been recalled due to benzene

phenyl radicals can then produce benzene. See Shang-Hao Liu et al., *Thermal hazard evaluation of the autocatalytic reaction of benzoyl peroxide using DSC and TAM III*, THERMOCHIMICA ACTA, Volume 605, (2015), Pages 68-76, ISSN 0040-6031, <https://www.sciencedirect.com/science/article/pii/S004060311500057X> (last visited Feb. 5, 2024).

²⁸ Food and Drug Administration. (Dec. 22, 2022). *FDA Alerts Drug Manufacturers to the Risk of Benzene in Certain Drugs*.

²⁹ Food and Drug Administration. *Reformulating Drug Products That Contain Carbomers Manufactured With Benzene* (December 27, 2023), <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reformulating-drug-products-contain-carbomers-manufactured-benzene>.

³⁰ *Id*; see also December 22, 2022 FDA Alert at 1.

1 contamination.

2 31. Defendant knew or should have known through their own research, development,
3 formulation, evaluation, selection, and testing of BPO Products whether they were chemically and
4 physically stable. Defendant was required not only to adequately test the BPO Products for safety and
5 stability before selling them to the public, but also to monitor their internal practices, processes, and
6 specifications to make sure they kept pace with science and emerging methodologies. Defendant
7 knew or should have known from expiration and stability studies examining the “shelf life” of the
8 BPO Products, the chemical changes took place because of normal and expected environmental, use,
9 and storage conditions.

10 32. Defendant knew or should have known the BPO Products would be handled, used, and
11 stored by distributors, sellers, and consumers under various temperatures that affect chemical stability.
12 Defendant knew or should have known the BPO Products would travel by commercial carriers and
13 distributors in varying storage conditions and would be stored by consumers in handbags, backpacks,
14 bathrooms, showers, lockers, and in vehicles during warm months where the BPO Products would be
15 exposed to heat. Defendant knew or should have known consumers would apply the benzene
16 contaminated BPO Products to their faces and bodies and would also use the BPO Products in heated
17 showers as scrubs and washes. Defendant knew or should have known the BPO Products would be
18 used and applied to the skin at normal body temperatures, and elevated temperatures following
19 showers or baths, after physical activity, and after the BPO Products sat in warm temperatures or hot
20 vehicles.

21 33. These storage, use, and handling conditions were known or should have been known to
22 Defendant before the BPO Products were marketed and sold to Plaintiff, the Class, and Subclass
23 members. Defendant knew or should have known the BPO Products degrade to benzene under these
24 conditions exposing consumers to benzene. Defendant further knew or should have known that,
25 because of the known degradation of BPO to benzene, their BPO Products were contaminated with
26 benzene by the time they reached consumers, but they sold them to Plaintiff, the Class, the Subclass,
27 and the public anyway, without warning of the risk of exposure. Moreover, the 2–3-year shelf life
28 printed on the BPO Products told consumers they were safe for use for years, when they were not.

C. DEFENDANT KNEW OR SHOULD HAVE KNOWN BENZENE WAS FOUND IN OTHER CONSUMER PRODUCTS BUT DID NOT TEST THEIR BPO PRODUCTS

34. Defendant was aware or should have been aware of benzene contamination in other on-market drug and healthcare products when they marketed and sold the BPO Products to Plaintiff, the Class, the Subclass, and the public but did not test the BPO Products for benzene contamination.

35. In 2020, the FDA started working with companies to identify benzene in products, which resulted in product recalls of hand sanitizers, sunscreens, and deodorants. In 2021, an independent chemical analysis by Valisure of hundreds of sunscreens and after-sun care products from 69 brands found 27 percent of the batches had significant levels of benzene above the FDA 2 ppm limit.³¹ Johnson and Johnson's Aveeno and Neutrogena sunscreen lines sold by Target were among the most benzene contaminated products and were recalled.³² CVS's private brand after-sun care products were also highly contaminated with benzene. By 2021, Defendant was well aware of benzene contamination issues in its competitor's products but ignored the reports and continued to advertise and sell the BPO Products without testing them for benzene.

D. DEFENDANT IGNORED FDA'S BENZENE ALERT TO TEST BPO PRODUCTS

36. In 2022, the FDA issued a safety alert warning drug manufacturers of the risk of benzene contamination in certain drug products and drug components. The FDA reiterated the risk benzene exposure poses to public health and the drug manufacturers' obligations to test drug products under the U.S. Code of Federal Regulations, Title 21:

FDA reminds manufacturers they are required to establish scientifically sound and appropriate specifications and test procedures to assure drug components (active and inactive ingredients) and finished drug products conform to appropriate quality specifications (21 C.F.R. 211.84, 21 C.F.R. 211.160). This includes testing of raw materials and finished batches (21 C.F.R. 211.165) prior to release to ensure they meet appropriate specifications for identity, strength,

³¹ Valisure Citizen Petition on Benzene in Sunscreen and After-sun Care Products, May 24, 2021.

³² Press Release. (July 14, 2021), Johnson & Johnson Consumer Inc. *Johnson & Johnson Consumer Inc. Voluntarily Rec of Specific Neutrogena and Aveeno Aerosol Sunscreen Products Due to the Presence of Benzene.*

quality, and purity.³³

37. The FDA warned drug manufacturers that any drug products or components at risk of benzene contamination should be tested, and any batches with benzene above 2 ppm should not be released to the public.³⁴ The FDA further warned that, if any drug or drug component was subject to deterioration, drug manufacturers must have re-testing procedures in place to ensure continued purity and stability. The FDA recommended risk assessments to evaluate the possibility of benzene contamination in the drug products or components.³⁵ If any drug product in circulation was found to have benzene over 2ppm, the FDA directed that drug manufacturers contact the FDA to discuss a voluntarily recall.³⁶

38. To date, none of the Defendant's Products have been recalled due to benzene contamination.

E. RECENT TESTING FOUND COMMON BPO PRODUCTS CONTAIN DANGEROUS LEVELS OF BENZENE IN EXCESS OF REGULATORY LIMITS

39. Testing by Valisure in 2023 found common acne treatment products formulated with BPO are not only contaminated with benzene but have levels dangerous to public health. Valisure is an accredited independent laboratory who has developed validated analytical methods³⁷ to test drugs and consumer products to address rising concerns about public safety. Valisure has tested a wide variety of drugs and products for benzene including sunscreens, antiperspirants, hand sanitizers, and dry shampoos. Their work has led to widely publicized product recalls protecting the public from dangerous and carcinogenic consumer products.³⁸

³³ Federal Drug Administration. (Dec. 22, 2022). *FDA Alerts Drug Manufacturers to the Risk of Benzene in Certain Drugs*, 1.

³⁴ *Id.*, 3.

³⁵ *Id.*

³⁶ *Id.*, 2.

³⁷ Valisure's test methods largely mirror those utilized by FDA's own "Drug Quality Sampling and Testing" ("DQST") Program. Valisure FDA Citizen's Petition at 4.

³⁸ See Valisure May 24, 2021 Citizen Petition on Benzene in Sunscreen and After-sun Care Products, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-sunscreen>; Valisure's Citizen Petition on Hand Sanitizer Products Containing Benzene Contamination (filed March 24, 2021), <https://www.regulations.gov/document/FDA-2021-P-0338-0001>, Valisure's Citizen Petition on Benzene in Sunscreen and After-sun Care Products (filed May 24, 2021),

40. In 2023, Valisure tested 175 finished acne treatment products to determine whether any had benzene. Of the 175 products tested, 99 were formulated with BPO, 58 had active ingredients (either individually or in combination) of salicylic acid, sulfur, adapalene, azelaic acid, niacinamide and zinc, and 18 had no drug ingredients.³⁹ 83 of the BPO Products were purchased over the counter from major retailers and 16 were prescription products purchased from licensed wholesalers.⁴⁰ The BPO Products included popular Products: Proactiv 2.5% BPO Cream, Target Up & Up 2.5% BPO Cream, Equate Beauty 10% BPO Cream, Equate BPO Cleanser, Neutrogena 10% BPO Cleanser, Clearasil 10% BPO Cream, CVS Health 10% BPO Face Wash, Walgreens 10% BPO Cream, La Roche Posay BPO Cream, and Clean & Clear 10% BPO Lotion.

41. Valisure used three incubation temperatures to evaluate the effects of common distributor and consumer use, handling, and storage conditions on benzene formation. 37°C/98.6°F was used for human body temperature, 50°C/122°F was used to evaluate shelf-life performance as an accelerated stability testing temperature used by the pharmaceutical industry,⁴¹ and 70°C/158°F to

<https://www.regulations.gov/document/FDA-2021-P-0497-0001>), Valisure's Citizen Petition on Benzene in Body Spray Products (filed November 3, 2021, <https://www.regulations.gov/document/FDA-2021-P-1193-0001>), Valisure's Citizen Petition on Benzene in Dry Shampoo Products (filed October 31, 2022), <https://www.regulations.gov/document/FDA-2022-P-2707-0001>) *see also* CNET, Dry Shampoo Recall: What Is Benzene and Which Brands Are Affected <https://www.cnet.com/health/personal-care/dry-shampoo-recall-what-is-benzene-and-which-brands-are-affected/> (identifying 19 types of dry shampoo have been recalled due to benzene content); Ryan Basen, Medpage Today, After Valisure Petition, Ol' Dirty Benzene Forces Another Recall (November 30, 2021), <https://www.medpagetoday.com/special-reports/exclusives/95929> ("After Valisure Petition, Ol' Dirty Benzene Forces Another Recall"); Bruce Y. Lee, Forbes, FDA: P&G Recalls Antiperspirant Sprays Due To Cancer Risk Of Benzene (Nov. 24, 2021), <https://www.forbes.com/sites/brucelee/2021/11/24/fda-pg-recalls-antiperspirants-body-sprays-due-to-cancer-risk-of-benzene/?sh=69cf13c24f32>; *see also* Sandee LaMotte, CNN, Antiperspirant recall: What the finding of a cancer-causing chemical means for you (Dec. 1, 2021), <https://www.cnn.com/2021/12/01/health/deodorants-antiperspirants-recall-benzene-explainer-wellness/index.html>.


³⁹ *See* Valisure Citizen's Petition on Benzoyl Peroxide (March 4, 2024).

⁴⁰ *Id.*


⁴¹ Ghimire, Prakash et al., *Guidelines on Stability Studies of Pharmaceutical Products and Shelf Life Estimation*. INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACY AND BIOTECHNOLOGY, (2020). 06. 15-23. 10.38111/ijapb.20200601004.

model storage in a hot vehicle.⁴² The BPO Products were incubated at 37°C for four weeks and 50°C for three weeks and benzene concentration was measured at certain time intervals using GC-MS. Benzene findings were plotted in real time and reported in parts per million (“ppm”). The results below were submitted to the FDA in Valisure’s March 5, 2024 Citizen’s Petition on Benzoyl Peroxide.⁴³

4A




4B




⁴² Grundstein A, Meentemeyer V, Dowd J. *Maximum vehicle cabin temperatures under different meteorological conditions*. Int J Biometeorol. 2009 May;53(3):255-61. doi: 10.1007/s00484-009-0211-x. Epub 2009 Feb 21. PMID: 19234721.

⁴³ Valisure, LLC, (March 6, 2024), *Valisure Discovers Benzoyl Acne Treatment Products are Unstable and Form Benzene*, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide> (last visited March 6, 2024).


4C




4D




4E




4F



4G



4H



42. Valisure found the BPO formulated products were not chemically stable and yielded benzene at levels well over 2 ppm, the maximum amount allowed in any U.S. regulated drug. Some of the benzene levels were 800 times higher than 2 ppm reaching as high as 1700 ppm.⁴⁴ The

⁴⁴ *Id.*

1 concentration of BPO in the Products did not influence the benzene levels, e.g., Target's Up & Up
 2 BPO Lotion and Proactiv's 10% BPO Cream yielded similar benzene results in the range of 600 ppm.
 3 Unexpectedly, Valisure found that benzene vapors leaked from some of the tested Products'
 4 packaging contaminating the surrounding air even when the packaging was closed raising concern for
 5 additional inhalation exposures.⁴⁵

6 43. Valisure concluded that all on-market BPO acne formulations are fundamentally
 7 unstable and form unacceptably high levels of benzene under normal use, handling, and storage
 8 temperatures, but no such evidence was observed for acne treatment products not formulated with
 9 BPO.⁴⁶ The finding that additional benzene leaked into the surrounding air from the products'
 10 containers means the total consumer benzene exposure would be even more dangerous than the levels
 11 reported.

12 44. Valisure filed a Citizen's Petition on Benzoyl Peroxide on March 5, 2024⁴⁷ with the
 13 FDA requesting the FDA Commissioner to immediately demand a recall of all BPO Products
 14 formulated with BPO and further to require that drug manufacturers do independent chemical
 15 verification.

16 **F. DEFENDANT EXPOSED PLAINTIFF, THE CLASS, AND THE PUBLIC TO**
 17 **BENZENE, A KNOWN HUMAN CARCINOGEN, WITHOUT THEIR**
 18 **KNOWLEDGE**

19 45. Although benzene has been found in the BPO Products and released into the
 20 surrounding air from the packaging, Defendant did not list benzene among the Products' ingredients,
 21 on the Products' label or container, or anywhere in their advertising or on their websites. Defendant
 22 did not (and still do not) warn that the Products contain benzene, are at risk of benzene contamination,
 23 or that the product could cause consumers to be exposed to benzene even when sealed.

24 46. Benzene is a carcinogen that has been among the most studied toxins over the last 100
 25 years due to its wide use during the industrial revolution, extreme danger, and known ability to cause
 26 cancer and death in humans and animals. The medical literature linking benzene to blood cancers is

27 ⁴⁵ *Id.*

28 ⁴⁶ *Id.*

⁴⁷ As of the date of filing this Class Action, Valisure's FDA Petition is still pending.

1 vast dating to the 1930s.⁴⁸ Benzene is the foundation component for many chemicals used to make
 2 plastics, resins, synthetic fibers, paints, dyes, detergents, drugs, and pesticides. In the past, benzene
 3 was widely used as a solvent in industrial paints, paint removers, adhesives, degreasing agents,
 4 denatured alcohol, and rubber cements. Benzene use has declined due to the proliferation of worker
 5 studies and an ever-growing body of evidence confirming benzene's contribution to blood cancers.

6 47. Benzene has no known safe level of exposure.⁴⁹ Benzene causes central nervous system
 7 depression and destroys bone marrow, leading to injury in the hematopoietic system.⁵⁰ The
 8 International Agency for Research on Cancer ("IARC") classifies benzene as a "Group 1 Carcinogen"
 9 that causes cancer in humans, including acute myelogenous leukemia ("AML").⁵¹ AML is the
 10 signature disease for benzene exposure with rates of AML particularly high in studies of workers
 11 exposed to benzene.⁵²

12 48. Benzene exposure is cumulative and additive. There is no safe level of exposure to
 13 benzene, and all exposures constitute some risk in a linear, if not supralinear, and additive fashion."⁵³

14 49. The Agency for Toxic Substances and Disease Registry's ("ATSDR") "Tox Facts" for
 15 benzene warns that people can be exposed to benzene vapors from benzene-containing products and
 16 that benzene harms the blood marrow, causing leukemia and anemia, and affects the immune system
 17 leaving victims vulnerable to infection.⁵⁴

18 ⁴⁸ See Hamilton A., *Benzene (benzol) poisoning*, ARCH PATHOL, (1931):434-54, 601-37; Hunter
 19 FT, *Chronic exposure to benzene (benzol). Part 2: The clinical effects*. J. IND. HYG TOXICOL,
 20 (1939):21 (8) 331-54; Mallory TB, et al., *Chronic exposure to benzene (benzol). Part 3: The*
 21 *pathological results*. J. IND. HYG TOXICOL, (1939):21 (8) 355-93; Erf LA, Rhoads CP., *The*
 22 *hematological effects of benzene (benzol) poisoning*. J. IND. HYG TOXICOL, (1939):21 421-35;
 23 American Petroleum Institute, *API Toxicological Review: Benzene*, NEW YORK, (1948); Infante PF,
 24 Rinsky RA, Wagoner JK, et al., *Leukemia in benzene workers*, LANCET, (1977);2 (8028): 76-78.

25 ⁴⁹ Harrison R, Saborit, J., *WHO Guidelines for Indoor Air Quality – Selected Pollutants*, (2010); see
 26 also Smith, Martyn T. (2010). *Advances in Understanding Benzene Health Effects and Susceptibility*.
 27 *Annual Review of Public Health*, (2010) Vol. 31:133-148.

28 ⁵⁰ FDA Toxicological Data for Class 1 Solvents, Appendix 4, *Benzene*,
<https://www.fda.gov/media/71738/download>.

⁵¹ International Agency for Research on Cancer. *Benzene, IARC Monographs on the Evaluation of*
Carcinogenic Risks to Humans, Volume 120, LYON, France: World Health Organization, (2018).

⁵² American Cancer Association, *Benzene and Cancer Risk*, [https://www.cancer.org/cancer/risk-](https://www.cancer.org/cancer/risk-prevention/chemicals/benzene.html)
[prevention/chemicals/benzene.html](https://www.cancer.org/cancer/risk-prevention/chemicals/benzene.html) (last visited October 20, 2023).

⁵³ Smith, Martyn T., *Annual Review of Public Health*, ADVANCES IN UNDERSTANDING
 BENZENE HEALTH EFFECTS AND SUSCEPTIBILITY (2010) Vol. 31:133-148.

⁵⁴ Agency for Toxic Substances and Disease Registry, *Benzene – Tox Facts*, CAS # 71-43-2.

50. According to the FDA, benzene in small amounts over long periods of time can decrease the formation of blood cells and long-term exposure through inhalation, oral intake, and skin absorption may result in cancers such as leukemia and other blood disorders.⁵⁵

51. Benzene is a major industrial chemical made from coal and oil that is heavily regulated by the EPA as an important environmental pollutant that negatively affects the soil, air, and groundwater. Waste and air emissions containing benzene are considered hazardous waste. The coal, oil, paint, and chemical industries are heavily regulated due to the emission of carcinogens including benzene from refining and other industries processes involving benzene and benzene byproducts, which can end up in the air, water, and food supply.

52. Benzene is heavily regulated to protect public health and should not be in drug products, especially ones such as acne treatment that are used daily by children and teenagers for many years. The FDA drug guidelines specify that benzene must not be used to make drugs products because of the unacceptable toxicity and deleterious environmental effects.⁵⁶ The FDA allows one limited exception – where the use of benzene in a drug product is unavoidable to produce a drug product with a significant therapeutic advance. In that instance, benzene must be restricted to two parts per million (ppm).⁵⁷ Defendant’s BPO Products do not meet this rare exception.

53. Benzene is heavily regulated in the workplace. The U.S. Occupational Safety and Health Administration (“OSHA”) set an eight-hour exposure standard of 1 ppm.⁵⁸ The National Institute for Occupational Safety and Health (“NIOSH”) established a recommended exposure level (REL) of 0.1 ppm (15-minute ceiling limit). Subsequent exposure studies known as the “China studies” confirmed cancer at levels below 1 ppm.⁵⁹ The benzene levels created from Defendant’s

⁵⁵ Federal Drug Administration. (June 9, 2022). *Frequently Asked Questions*: <https://www.fda.gov/drugs/drug-safety-and-availability/frequently-asked-questions-benzene-contamination-drugs>.

⁵⁶ Food and Drug Administration, *Q3C – Tables and Lists Guidance for Industry*, <https://www.fda.gov/media/71737/download> (last visited September 26, 2023).

⁵⁷ *Id.*

⁵⁸ OSHA. Occupational exposure to benzene: Final rule. Fed. Reg. 1987;52-34460-578.

⁵⁹ See Lan Q, Zhang L et al., *Hematotoxicity in Workers Exposed to Low Levels of Benzene*, SCIENCE, (December 3, 2004); Costa-Amaral I, V. B. L., *Environmental Assessment and Evaluation of Oxidative Stress and Genotoxicity Biomarkers Related to Chronic Occupational Exposure to Benzene*, INT J ENVIRON RES PUBLIC HEALTH, (2019) Jun; 16(12): 2240.

1 BPO Products are many times higher than the levels reported in these worker studies and the
2 acceptable limits set by regulators.

3 54. Benzene can also pass from the mother's blood to a developing fetus causing the baby
4 to be exposed to benzene.⁶⁰ Animal studies have shown low birth weights, delayed bone formation,
5 and damage to the bone marrow of developing offspring when pregnant animals breathed benzene.⁶¹

6 55. Plaintiff and the Class were exposed to benzene from the BPO Products by inhalation
7 and dermal absorption. Benzene can be absorbed into the body via inhalation, skin absorption,
8 ingestion, and/or eye contact.⁶² Plaintiff and the Class applied the BPO Products to areas of the skin
9 including the face, neck, chest, and back one to three times per day and used the BPO Products as
10 washes or scrubs in heated showers. Plaintiff and the Class were also exposed to benzene leaked from
11 contaminated BPO Products.

12 **G. DEFENDANT MARKETING ITSELF AS A COMPANY OF INTEGRITY BUT**
13 **CONCEALED FROM CONSUMERS THEIR FAILURE TO TEST THE BPO**
14 **PRODUCTS FOR SAFETY**

15 56. Defendant's BPO Products degrade to benzene under normal and expected handling,
16 use, or storage but Defendant did not warn Plaintiff, the Class, the Subclass, and the public about the
17 risk of benzene contamination or the health risks of exposure. Instead, Defendant made broad
18 sweeping claims that its BPO Products were safe, and that it was a company of innovation and
19 integrity leading consumers to believe it would not sell a benzene contaminated Product.⁶³

20 57. Defendant told Plaintiffs, the Class, and Subclasses the Aspexia Acne Spot Treatment
21 10% BPO Cream, was the "skincare expert for deep cleansing."⁶⁴ Defendant's advertising frequently
22 featured teenagers using the BPO Product they said, "penetrated deeply into the pores."

23 58. Defendant's affirmations of safety, misrepresentations and omissions of material safety

24 ⁶⁰ *Id.*

25 ⁶¹ *Id.*

26 ⁶² Centers for Disease Control and Prevention, *The National Institute for Occupational Safety and Health Pocket Guide to Chemical Hazards, Benzene Exposure Limits*,
27 <https://www.cdc.gov/niosh/npg/npgd0049.html>.

28 ⁶³ *Id.*

⁶⁴ Genomma Lab, *Aspexia Spot Treatment Cream with 10 Benzoyl Peroxide*,
<https://mygenommalab.com/products/asepxia-spot-acne-treatment-cream-with-10-benzoyl-peroxide-1-oz> (last visited November 6, 2023).

1 information misled Plaintiff, the Class, the Subclass, and the public regarding the safety, stability, and
2 quality of the BPO Products. Defendant's affirmations of safety and integrity gave Plaintiff, the Class,
3 the Subclass, and the public a false sense of safety. Defendant made these statements uniformly to
4 Plaintiff, the Class, the Subclass, and the public. Defendant's statements and affirmations were false,
5 misleading, unsubstantiated, and blatantly deceptive.

6 **H. DEFENDANT DID NOT WARN PLAINTIFF, THE CLASS, AND SUBCLASS**
7 **THE BPO PRODUCTS WERE AT RISK OF BENZENE CONTAMINATION**

8 59. Defendant represented to the Plaintiff, the Class, the Subclass, and the public, that the
9 BPO Products had only the ingredients listed on the Product's label, container, advertising, and
10 packaging. Defendant never identified benzene anywhere on the Product, or its label, container, or
11 packaging. Defendant never disclosed benzene, or that the Product was at risk for degradation to
12 benzene on any of its websites or Product containers.

13 60. Defendant's statements about the BPO Products' ingredients were false, deceptive, and
14 misleading. Defendant's statements were meant to convey to Plaintiff, the Class, the Subclasses, and
15 the public the Products were safe and did not contain carcinogens such as benzene. Defendant made
16 these statements uniformly to consumers and specifically omitted benzene from all advertising,
17 labeling, and packaging when they knew or should have known the statements were false, misleading,
18 and deceptive. Reasonable consumers, relying on Defendant's statements reasonably believed the
19 BPO Products were safe and did not contain benzene.

20 **I. DEFENDANT DIRECTLY MARKETING THE BPO PRODUCTS TO**
21 **CHILDREN AND TEENAGERS**

22 61. Defendant's BPO Products are widely used by children and teenagers as a standalone
23 treatment or in combination with other BPO Products. Defendant knew that adolescents are the largest
24 users with users as young as 7-10 years old. Defendant recommended that consumers, including
25 children, use the BPO Products one to three times a day, over many months or longer for persistent
26 acne. Defendant knew that some consumers would use the BPO Products for many years starting in
27 their teens. There is no cure for acne. Defendant knew that consumers with chronic acne would use
28 their BPO Products several times a day throughout their lifetime.

62. Defendant aggressively marketed the BPO Products directly to children and teenagers knowing, or they should have known, the BPO Products degrade to benzene under normal use and storage conditions. Many of Defendant's online and print advertisements featured children, teenagers, eye-catching props, music, and colors meant to attract teens and pre-teens, and appeal to their preferences, activities, and interests.

63. Defendant's marketing of BPO Products without mentioning benzene, the risk of benzene exposure, or testing for benzene waste and continues to be misleading, fraudulent, deceptive, and dangerous.

V. PUNITIVE DAMAGES ALLEGATIONS

64. Defendant's conduct was done with malice and reckless disregard for human life. Defendant knew the BPO Products degraded to benzene when exposed to heat under normal consumer use, handling, and storage conditions. Defendant further knew that benzene is a known human carcinogen that is not supposed to be in the BPO Products due to the grave risk of harm to consumers. Defendant disregarded this information and the known risks of benzene exposure and deliberately omitted benzene from the list of ingredients, the BPO Products' labels, and their social media and websites where information about the BPO Products is found. Defendant consciously and deliberately crafted the BPO Products' marketing, labels, packaging, containers, and warnings intending to mislead Plaintiff, the Class, the Subclasses, and the public, and lead them to believe the BPO Products were safe and carcinogen-free.

65. Defendant is a leading pharmaceutical company that marketed itself as an innovator with integrity, while at the same time withholding material information Defendant knew was essential to informed consumer decision making. Defendant knew that, by their conduct, they were robbing Plaintiff, the Class, the Subclasses, and the public of their right to choose safe products.

66. Defendant was on notice of benzene findings in consumer products, which lead to widely publicized product recalls. Defendant was on notice of the FDA's concerns of benzene contamination in drug and consumer products and received the FDA's 2022 directive to test Products for benzene contamination. Defendant disregarded these notices and continued to market and sell the BPO Products to the public without testing them for benzene.

67. Defendant knew its decisions and chosen course of conduct was risky and would cause consumers to be exposed to benzene. Defendant's conduct was not by accident, but was deliberate, calculated, and informed. Defendant knew they could sell more BPO Products and earn more money by concealing material human health and safety information. Defendant further knew that testing the BPO Products for benzene would yield findings of benzene requiring recalls and/or a shutdown of causing significant losses of income. Defendant's goals were met not only because of their false and deceptive advertising, labeling, and packaging, but through a comprehensive scheme of aggressive marketing and image branding leading consumers to believe they were consumer conscious retailers dedicated to safety. Defendant's conduct and concealment of material health and safety information was done to further their own monetary gain and with conscious disregard of the Plaintiff, the Class, the Subclasses, and the public's right to choose safe products. Defendant's conduct was intentional, calculated, blatantly deceptive, unscrupulous, and offensive to consumer health and public policy. To redress the harms caused by Defendant's conduct, Plaintiff, on behalf herself, the Class, and Subclasses, seek punitive damages against the Defendant.

VI. PLAINTIFF SPECIFIC ALLEGATIONS

68. Plaintiff Chinyere Harris is a California resident who places a high priority on health and safety, and on the adverse health consequences of exposure to carcinogens such as benzene. In shopping for drug products for her skin and face, Plaintiff Chinyere Harris was particularly concerned about the effectiveness to control the pimples and blackheads on her face. Plaintiff read the front labeling of the product which encouraged her to purchase the product by Defendants. Based on the statements made by Defendants, their widely recognized name, and lack of information that the BPO Products contained carcinogens such as benzene, Plaintiff believed the BPO Products were safe to put on her skin. Defendants' representations and omissions of human health and safety information were material to Plaintiff.

69. Plaintiff Harris bought Asepxia Acne Spot Treatment Cream for Pimples and Blackheads and used it from July 2022 to November 2023 for breakouts on her face such as cheeks and chin. Plaintiff was unaware when she bought the BPO Products that it was contaminated with benzene or that it could degrade to benzene. Had Defendants been truthful and told Plaintiff she would

1 be exposed to benzene and/or be at increased risk of cancer, she would not have purchased Asepxia
2 Acne Spot Treatment Cream for Pimples and Blackheads.

3 70. Plaintiff Harris suffered an ascertainable economic loss because of Defendant's
4 statements and misrepresentations in that he bought the BPO Products she would not have bought but
5 for Defendant's statements and misrepresentations.

6 **VII. CLASS ACTION ALLEGATIONS**

7 71. Plaintiff brings this case on behalf of herself, and all others similarly situated as a Class
8 Action under Rule 23 of the Federal Rules of Civil Procedure. Plaintiff seeks to represent a National
9 Class of consumers who bought the Products, and State Subclasses of consumers from the states
10 identified below. Excluded from this Class are Defendant, their employees, co-conspirators, officers,
11 directors, legal representatives, heirs, successors, and affiliated companies; Class counsel and their
12 employees; and judicial officers and their immediate families as court staff assigned to the case.

13 72. The Class does not seek damages for physical injuries, although Plaintiff was physically
14 harmed by being exposed to benzene.

15 73. The Class will include a National Class to include all persons who bought for use, and
16 not resale, the Products within the United States.

17 74. The State Subclasses will include all persons who bought for use, and not resale, the
18 Products within California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New
19 York, Nevada, Ohio, Pennsylvania, Rhode Island, and Washington.

20 75. This action has been brought and may be properly maintained as a Class Action under
21 Rule 23 of the Federal Rules of Civil Procedure because there is a well-defined community of interest
22 and the proposed Class meets the class action requirements under Rule 23 of numerosity,
23 commonality, typicality, and adequacy of representation.

24 76. Defendant engaged in a common course of conduct giving rise to the legal rights sought
25 to be enforced by Plaintiff, on behalf of herself, and the other Class members. Similar or identical
26 statutory and common law violations, business practices, and injuries are involved.

27 77. **Numerosity.** Plaintiff believes there are millions of Class members throughout the
28 United States, and there are tens of thousands of Subclass members in each of the listed states, making

the Class and state Subclasses so numerous and geographically dispersed that joinder of all members is inconvenient and impracticable.

78. **Commonality.** There are questions of law and fact common to all Class and Subclass members that predominate over questions which affect only individual Class members. All Class and Subclass members were deceived and misled by Defendant through the same advertising, online representations, labeling, and packaging, which do not mention benzene and misrepresent the characteristics, ingredients, and safety of the BPO Products. All Class and Subclass members bought Defendant's BPO Products and have suffered an economic loss because of Defendant's deceptions and omissions. Thus, there is a well-defined community of interest in the questions of law and facts common to all Class and Subclass members. Other common questions of law and fact in this dispute include, without limitation:

- a. Whether Defendant's BPO Products degrade to benzene under common distributor and consumer handling, use, and storage conditions.
- b. Whether Defendant tested the BPO Products for benzene before selling them to Plaintiff, the Class, and the public.
- c. When Defendant knew or should have known the BPO Products degraded to benzene.
- d. When Defendant knew or should have known the BPO Products contain benzene.
- e. Whether Defendant's advertising omitting benzene was deceptive, fraudulent, or unfair.
- f. Whether Defendant's advertising omitting benzene was likely to deceive reasonable consumers.
- g. Whether Defendant's conduct violated California's Unfair Competition Law, Bus. & Prof. Code § 17200 *et seq.*
- h. Whether Defendant's conduct violated California consumer protection laws.
- i. Whether Defendant's conduct violated Connecticut consumer protection laws.
- j. Whether Defendant's conduct violated Hawaii consumer protection laws.
- k. Whether Defendant's conduct violated Illinois consumer protection laws.
- l. Whether Defendant's conduct violated Massachusetts consumer protection laws including Mass. Gen. Laws Ann. Ch. 93A, § 1 *et seq.*

- m. Whether Defendant's conduct violated Maryland consumer protection laws.
- n. Whether Defendant's conduct violated Missouri consumer protection laws including Mo. Rev. Stat. § 407, *et seq.*
- o. Whether Defendant's conduct violated Nevada consumer protection laws including Deceptive Trade Practice Act, NEV. REV. STATUTES, Title 52, Chapter 598 *et seq.*
- p. Whether Defendant's conduct violated New York consumer protection laws including New York Deceptive Trade Practices Law, NY Gen. Bus. §349(a) and NY Gen. Bus. §§ 350 *et seq.*
- q. Whether Defendant's conduct violated Pennsylvania consumer protection laws.
- r. Whether Defendant's conduct violated Rhode Island consumer protection laws.
- s. Whether Defendant's conduct violated Washington's consumer protection laws.
- t. Whether Defendant breached the express and implied warranties they made about the BPO Products.
- u. Whether Defendant was unjustly enriched by the Plaintiff, the proposed Class, and Subclasses members' purchase of the BPO Products.
- v. Whether the Plaintiff, the proposed Class, and Subclasses have been injured and if so, what is the proper measure of damages.
- w. Whether the Plaintiff, the proposed Class, and Subclasses have the right to economic damages including compensatory, exemplary, and statutory remedies for Defendant's misconduct.
- x. Whether the Plaintiff, the proposed Class, and Subclasses have the right to injunctive, declaratory, or other equitable relief and attorneys' fees.

79. **Typicality.** Plaintiff's claims are typical of the claims of the Class and Subclasses because the claims arise from the same course of misconduct by Defendant, *i.e.*, Defendant's false and misleading advertising and their failure to disclose benzene in the Products. The Plaintiff, and all Class and Subclass members were all exposed to the same uniform and consistent advertising, labeling, and packaging statements Defendant made about the Products. Because of the Defendant's misconduct, Plaintiff, like all Class members, was damaged and has incurred economic loss because

1 of buying the Products believed to be safe. The claims of the Plaintiff are typical of Class members.

2 80. **Adequacy.** The Plaintiff will fairly and adequately represent and protect the interests of
3 all Class and Subclass members. Plaintiff has no interests antagonistic to the Class or Subclass
4 members. Plaintiff hired attorneys experienced in the prosecution of consumer Class Actions and
5 Plaintiff intends to prosecute this action vigorously. Plaintiff anticipates no difficulty in the
6 management of this litigation as a Class Action.

7 81. Finally, this Class Action is proper under Rule 23(b) because, under these facts, a Class
8 Action is superior to other methods and is the most efficient method for the fair and efficient
9 adjudication of the dispute. The Class and Subclass members have all suffered economic damages
10 because of Defendant's deceptive trade practices, false advertising, and omissions of material health
11 and safety information. Because of the nature of the individual Class and Subclass members' claims
12 and the cost of the Products, few, if any individuals, would seek legal redress against Defendant
13 because the costs of litigation would far exceed any potential economic recovery. Absent a Class
14 Action, individuals will continue to suffer economic losses for which they would have no remedy, and
15 Defendant will unjustly continue their misconduct with no accountability while retaining the profits of
16 their ill-gotten gains. Even if separate cases could be brought by individuals, the resulting multiplicity
17 of lawsuits would cause undue hardship, burden, and expense for the Court and the litigants, as well
18 as create a risk of inconsistent rulings across the country, which might be dispositive of the interests
19 of individuals who are not parties. A Class Action furthers the important public interest of containing
20 legal expenses, efficiently resolving many claims with common facts in a single forum
21 simultaneously, and without unnecessary duplication of effort and drain on critical judicial resources.
22 The Class Action method presents far fewer management difficulties than individual cases filed
23 nationwide and provides the benefit of comprehensive supervision by a single court.

24 **VIII. CAUSES OF ACTION**

25 **A. VIOLATION OF CALIFORNIA'S UNFAIR COMPETITION LAW *Bus. & Prof.*** 26 ***Code § 17200 et seq., on Behalf of the California Subclass***

27 82. Plaintiff realleges and incorporates all other paragraphs in this Class Action Complaint
28 and further alleges:

1 83. Plaintiff brings this cause of action on behalf of herself, and all members of the
2 California Subclass, all of whom are similarly situated consumers.

3 84. California's Unfair Competition Law, CAL. BUS. & PROF. CODE § 17200, *et seq.*,
4 prohibits "unlawful, unfair, or fraudulent business act or practices" and "unfair, deceptive, untrue or
5 misleading advertising." Defendant regularly transacts business in California, including in this
6 District, and has engaged in misconduct that has had a direct, substantial, foreseeable, and intended
7 effect of injuring people in California, and in this District.

8 85. Defendant misrepresented their Products in advertising, labels, and containers and
9 misled Plaintiff, the Subclass, and the public about the ingredients, characteristics, purity, quality,
10 approval, and safety of the Products. Defendant led Plaintiff, the Subclass, and the public to believe
11 the Products were safe.

12 86. Defendant's advertising, online representations, labeling, and packaging of the Products
13 were misleading, fraudulent, and deceptive. Defendant knew through the Products' development,
14 formulation, research, and pre-sale safety and stability testing, the Products were not chemically and
15 physically stable when exposed to common temperature conditions. Defendant knew or should have
16 known the Products formulated benzene under normal and expected consumer use, handling, and
17 storage conditions, and that consumers would be exposed to benzene. Defendant were specifically
18 reminded by the FDA of their obligation to ensure the safety and quality of their Products, including
19 testing them for benzene before selling them to the public, but shirked their duties and continued to
20 market and sell the Products without substantiating their safety, or warning Plaintiff, the Class, and
21 the public about benzene.

22 87. Defendant omitted material health and safety information, *e.g.*, benzene, from the
23 Products' advertising, label, container, and warnings. Defendant did not tell Plaintiff and the Class
24 members they would be exposed to benzene, a human carcinogen, during normal and expected
25 handling, use and storage of the Products, even with the Products' container closed.

26 88. Defendant's acts and omissions were likely to deceive reasonable consumers and the
27 public. Reasonable consumers expect to be told about all ingredients in Products. Reasonable
28 consumers further expect that carcinogens in the Products be disclosed. Reasonable consumers further

1 expect that on market drugs to be free of carcinogens, unless told otherwise. Benzene in a widely
2 marketed drug product used by children, teens, and the public is material health information
3 reasonable consumers expect to be told.

4 89. Had Defendant been truthful in their advertising, labeling, packaging, and online
5 statements about benzene in the Products, or the risk of contamination, and the risk of cancer, Plaintiff
6 and the Class members would not have bought the Products.

7 90. Defendant's acts, omissions, and concealment of material health and safety information
8 are ongoing and continuing to cause harm. Defendant continued to market, advertise, and sell the
9 Products to the public without telling the public about benzene in the Products, or the risk of
10 contamination, and the risk of cancer. Defendant continued to market themselves as responsible drug
11 manufacturers and sellers who sell safe products when they have not tested the Products for benzene
12 or quantified the levels of benzene formed in the Products during normal and expected storage
13 conditions.

14 91. Defendant engaged in these deceptive practices for significant financial gain, which is
15 unfair, unreasonably dangerous to Plaintiff and the California Subclass members, and not outweighed
16 by any benefit. Omitting and concealing material human health and safety information such as
17 benzene in the Product and the consumers' risk of cancer from the Products is unethical,
18 unscrupulous, and offensive.

19 92. Plaintiff suffered ascertainable economic losses because of Defendant's misconduct
20 because he bought the Products, he otherwise would not have bought but for Defendant's
21 misrepresentations and affirmations of safety.

22 93. Because of Defendant's misconduct, Plaintiff, on behalf of herself, and the California
23 Subclass, seek recovery of their economic damages, attorneys' fees, restitution, and all other relief
24 allowable under CAL. BUS. & PROF. CODE § 17200, *et seq.*, including an injunction to enjoin
25 Defendant from continuing their fraudulent and deceptive business practices. The damages sought are
26 ascertainable, uniform to the Class and can be measured and returned to the Class members.

27 ///

28 ///

B. VIOLATION OF CALIFORNIA’S CONSUMER LEGAL REMEDIES ACT, Cal. Civ. Code § 1750, et seq., on Behalf of the California Subclass

94. Plaintiff realleges and incorporates all other paragraphs in this Complaint and further alleges:

95. Plaintiff brings this cause of action on behalf of herself, and the California Subclass members, all of whom are similarly situated consumers within the meaning of CAL. CIV. CODE § 1781.

96. Defendant’s acts and omissions violated California’s Consumer Legal Remedies Act, CAL. CIV. CODE § 1750, *et seq.*, enacted to protect consumers from being victimized and deceived by advertisers, distributors, and sellers like the Defendant. Defendant regularly transacts business in California, including in this District, and has engaged in misconduct that has had a direct, substantial, foreseeable, and intended effect of injuring people in California, and in this District.

97. California’s Consumer Legal Remedies Act, CAL. CIV. CODE § 1750, *et seq. prohibits* unfair methods of competition and unfair or deceptive acts or practices in connection with the sale of consumer goods. Defendant violated several prohibitions of CIV. CODE § 1750(a).

98. Defendant violated CAL. CIV. CODE § 1750(a)(2) by representing the source, sponsorship, and approval, of the Products, *e.g.*, the Products were backed by sound scientific principles, that Defendant met its obligations to conduct adequate and meaningful quality and safety testing before selling the Products to the public, and represented the Products only contained the ingredients listed, and were free of carcinogens.

99. Defendant violated CAL. CIV. CODE § 1750(a)(3) by representing the affiliation, connection, or association with, or certification by, another *e.g.*, the Products were approved by dermatologists and manufactured in conformity with current good manufacturing practices.

100. Defendant violated CAL. CIV. CODE § 1750 (a)(4) by using deceptive representations, *e.g.*, the Products were safe, validated, and supported by the latest research, and free of carcinogens such as benzene.

101. Defendant violated CAL. CIV. CODE § 1750(a)(5) by representing the Products have characteristics, ingredients, uses, or benefits, which they do not, *e.g.*, misleading Plaintiff and the Class members the Products only contained the listed ingredients, did not contain benzene, and did not

1 increase the risk of the consumers' risk of cancer.

2 102. Defendant violated CAL. CIV. CODE § 1750(a)(6) by representing the Products were not
3 deteriorated unreasonably or altered *e.g.*, the Products were pure and had not degraded or formed
4 benzene.

5 103. Defendant violated CAL. CIV. CODE § 1750(a)(7) by representing the Products were
6 pure and of a particular standard or quality, when they are not.

7 104. Defendant violated CAL. CIV. CODE § 1750(a)(9) by advertising the Products with the
8 intent not to sell them as advertised, *e.g.*, the Products were of pure quality, safe, made in conformity
9 with current good manufacturing practices, and not adulterated.

10 105. Had Defendant been truthful in their advertising, labeling, packaging, warnings, and
11 online statements about benzene in the Products and the risk of cancer, Plaintiff and the California
12 Subclass members would not have bought the Products. Benzene, a human carcinogen, in a widely
13 marketed and available consumer drug product, is material health and safety information Defendant
14 knew Plaintiff, the Class members, and the public would want to know. The Defendant's omission of
15 this material information was common to Plaintiff and all Subclass members and made to Plaintiff and
16 all Subclass members uniformly through common advertising, online representations, labeling, and
17 packaging.

18 106. Defendant's acts, omissions, and concealment of material health and safety information
19 are ongoing and continuing to cause harm. Defendant continued to market, advertise, and sell the
20 Products to the public without telling the public about benzene in the Products and the risk of cancer.
21 Defendant continues to market themselves as responsible drug manufacturers and sellers who sell safe
22 products when they have not quantified the levels of benzene in and created in the Products during
23 normal and expected storage conditions.

24 107. Defendant engaged in these deceptive practices for significant financial gain, which is
25 unfair, unreasonably dangerous to Plaintiff and the Subclass members, and not outweighed by any
26 benefit. Omitting and concealing material human health and safety information such as the
27 consumers' risk of cancer from exposure to the Products is unethical, unscrupulous, and offensive.

28 108. Plaintiff suffered ascertainable economic losses because of Defendant's misconduct

1 because he bought the Products, she otherwise would not have but for Defendant's misrepresentations.

2 109. Because of Defendant's misconduct, Plaintiff, on behalf of herself and the California
3 Class seek recovery of their economic damages, attorneys' fees, punitive damages, restitution, and all
4 other relief allowable under CAL. CIV. CODE § 1750, *et seq.*, including an injunction to enjoin
5 Defendant from continuing their fraudulent business practices. The damages sought are ascertainable,
6 uniform to the Subclass and can be measured and returned to the Subclass members.

7 **C. FALSE ADVERTISING UNDER VARIOUS STATE STATUTES, on Behalf of the**
8 ***California, Hawaii and New York Subclasses***

9 110. Plaintiff realleges and incorporates all other paragraphs in this Complaint and further
10 alleges:

11 111. Plaintiff brings this cause of action on behalf of herself, and all members of the
12 California, Hawaii, and New York Subclasses, all of whom are similarly situated consumers.

13 112. Defendant develops, tests, selects, markets and/or sells the BPO Products throughout
14 the United States in its stores and through eCommerce websites. Defendant knew through the
15 Products' development, formulation, and selection, the Products were not chemically stable when
16 exposed to certain expected and normal environmental and storage conditions and formed benzene, as
17 a toxic byproduct. Despite this knowledge, Defendant did not mention benzene in the Products'
18 advertising, ingredient lists, labels, containers, or warnings. Defendant did not tell Plaintiff, and the
19 Subclass members they would be exposed to benzene, a human carcinogen, during normal and
20 expected handling, use and storage of the Products, even with the Products' containers closed.

21 113. Benzene, a human carcinogen, in a widely marketed and available consumer drug
22 product, is material health and safety information Defendant knew Plaintiff, and the Subclass
23 members would want to know. Defendant not only omitted this material human health and safety
24 information from advertising, online representations, blogs, labeling, packaging, and warnings, but
25 aggressively marketed itself as consumer conscious, a market leader, and company committed to
26 consumer safety. Defendant's brand notoriety, market share, and affirmations of safety misled
27 Plaintiff, and the Subclass members, leading them to believe the Products were tested, verified, and
28 safe. Defendant further marketed the Products touting the approval of dermatologists, who were not

1 aware of the presence of benzene in the Products and of Defendant's refusal to conduct adequate and
 2 meaningful testing before marketing and selling the Products to the public and following the FDA's
 3 2022 alert to specifically look for benzene.

4 114. Defendant's acts and omissions constitute false advertising. Defendant advertised the
 5 Products with the intent not to sell them as advertised. Reasonable consumers, including Plaintiff and
 6 the Subclass members, exposed to Defendant advertising would believe the Products were safe,
 7 verified, and free of benzene.

8 115. Defendant's false and misleading advertising violated California's False Advertising
 9 Law, Bus. & Prof. Code § 17500 *et seq.*, which prohibits Defendant from disseminating statements
 10 "which are untrue or misleading, and which are known, or which by the exercise of reasonable care
 11 should be known, to be untrue or misleading." Defendant knew or should have known the Products
 12 formed benzene under normal, handling, use, and storage conditions but did not disclose this to
 13 Plaintiff and the Class and Subclass members. Defendant knew or should have known the Products
 14 were not chemically stable when exposed to certain normal and expected environmental conditions.

15 116. Defendant's false and misleading advertising violated Hawaii's False Advertising Law,
 16 HI REV. STAT. § 708-871. Defendant knowingly or recklessly made false and misleading statements in
 17 the Products' advertising to the public.⁶⁵ Defendant further advertised the Products with the intent not
 18 to sell them as advertised and misrepresented the ingredients, quality, purity, safety, and character of
 19 the Products.

20 117. Defendant's false and misleading advertising violated New York's General Business
 21 Law § 350 *et seq.* ("GBL § 350"), which prohibits "[f]alse advertising in the misconduct of any
 22 business, trade or commerce or in the furnishing of any service" in New York. Under GBL § 350,
 23

24
 25 ⁶⁵ HI REV STAT § 708-871, False Advertising: (1) A person commits the offense of false advertising if,
 26 in connection with the promotion of the sale of property or services, the person knowingly or
 27 recklessly makes or causes to be made a false or misleading statement in any advertisement addressed
 28 to the public or to a substantial number of persons. (2) "Misleading statement" includes an offer to sell
 property or services if the offeror does not intend to sell or provide the advertised property or services:
 (a) At the price equal to or lower than the price offered; or (b) In a quantity sufficient to meet the
 reasonably- expected public demand unless quantity is specifically stated in the advertisement; or (c)
 At all.

“false advertising” includes “advertising, including labeling, of a commodity . . . if such advertising is misleading in a material respect.” Defendant violated GBL § 350 by advertising and selling the Products without disclosing material health and safety information, *e.g.*, benzene and the consumers risk of cancer from benzene. Defendant’s false and misleading advertising was directed at consumers, the New York Subclass members, and the public, and caused consumer injury and harm to the public interest.

118. Had Defendant been truthful in their advertising, online representations, labeling, and packaging about benzene, Plaintiff, and the Subclass members would not have bought the Products.

119. Plaintiff, on behalf of herself, and the California, Hawaii, and New York Subclass members suffered ascertainable economic losses because of Defendant’s misconduct because they bought the Products, they otherwise would not have but for Defendant’s material misrepresentations.

120. Because of Defendant’s misconduct, Plaintiff, on behalf of herself, and the California, Hawaii, and New York Subclass members, seek recovery of their economic damages, attorneys’ fees, punitive damages, restitution, and all other relief allowable by law, including an injunction to enjoin Defendant from continuing their fraudulent business practices. The damages sought are ascertainable, uniform, and can be measured and returned.

D. DECEPTIVE TRADE PRACTICES UNDER VARIOUS STATE STATUTES, on Behalf of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses

121. Plaintiff realleges and incorporates all other paragraphs in this Complaint and further alleges:

122. Plaintiff brings this cause of action on behalf of herself, and all members of the Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses, all of whom are similarly situated consumers.

123. Defendant’s acts and omissions constitute deceptive business practices in violation of state deceptive trade practices laws.

124. Defendant represented the BPO Products had characteristics, uses, and benefits, they did not, *e.g.*, Defendant represented the BPO Products were pure, of good quality, safe, and only

1 contained the ingredients disclosed.

2 125. Defendant represented the BPO Products were not deteriorated or altered, when they
3 knew, or should have known, the BPO Products degraded to benzene under normal and expected use,
4 handling, and storage conditions.

5 126. Defendant represented the BPO Products contained only the ingredients listed on
6 Defendant's websites, advertising, labels, and containers. Defendant did not disclose to Plaintiff, the
7 Class and Subclass members, and the public the BPO Products were at risk of benzene contamination.

8 127. Defendant advertised the BPO Products with the intent not to sell them as advertised.

9 128. Defendant's acts and omissions violated California's Consumer Legal Remedies Act,
10 CAL. CIV. CODE § 1750, *et seq.*, enacted to protect consumers from being victimized and deceived
11 by advertisers, distributors, and sellers like the Defendant.

12 129. Defendant's acts and omissions violated Connecticut Unfair Trade Practices Act, CONN.
13 GEN STAT. ANN., § 42- 110, *et seq.*, which broadly prohibits Defendant from engaging in unfair
14 methods of competition and unfair or deceptive acts or practices in the conduct of any trade
15 or commerce such as those committed by Defendant and alleged in this Class Action.

16 130. Defendant's acts and omissions violated Hawaii's Uniform Deceptive Trade Practice
17 Act, HAW. REV. STAT. §481-A3 because Defendant: (1) caused the likelihood of confusion or of
18 misunderstanding as to the source, sponsorship, approval, or certification of the Products; (2)
19 represented the Products had characteristics, ingredients, or benefits, they did not; (3) represented the
20 Products were not deteriorated or altered, when they were; (4) represented the Products were of a
21 particular standard or quality when they were not; and (5) advertised the Products with the intent not
22 to sell them as advertised.

23 131. Defendant's acts and omissions violated Illinois' Consumer Fraud and Deceptive
24 Business Practices Act, 815 ILCS 505/1 *et seq.* Defendant's used deception, fraud, false pretense,
25 false promises, and omitted material health and safety information about the Products' degradation to
26 benzene, and/or contamination with benzene, which Defendant intended the Illinois Subclass
27 members to rely upon.

28 132. Defendant's acts and omissions violated Maryland's Unfair or Deceptive Trade

1 Practices Act, MD. COM. CODE, Title 13, Subtitle 3, §13-301 because Defendant: (1) represented the
 2 Products had characteristics, ingredients, uses, and benefits, they did not; (2) represented the Products
 3 were not deteriorated or altered, when they were; (3) represented the Products were of a particular
 4 standard or quality, when they were not. Defendant's representations about the Products' ingredients,
 5 and omission of benzene were misleading, deceptive, incomplete, and not truthful in violation of
 6 Maryland's Unfair or Deceptive Trade Practices Act.

7 133. Defendant's acts and omissions violated Massachusetts consumer protection law, MASS.
 8 GEN. LAWS ANN. Ch. 93A, § 1 *et seq.*, which broadly prohibits unfair and deceptive trade practices
 9 such as those committed by Defendant and alleged in this Class Action.

10 134. Defendant's acts and omissions violated the Missouri Merchandising Practices Act, MO.
 11 REV. STAT. § 407, *et seq.*, which prohibits the use of deception, fraud, misrepresentations, or unfair
 12 practices by a business, *e.g.*, marketing Products as safe, approved, tested, and only containing the
 13 listed ingredients. Missouri's law further prohibits the suppression or omission of material facts such
 14 as the Products' degradation to benzene.

15 135. Defendant's acts and omissions violated N.Y. GEN. BUS. LAW § 349, which prohibits
 16 Defendant from engaging in deceptive, unfair, and misleading acts and practices such as those
 17 committed by Defendant and alleged in this Class Action. Defendant's misrepresentations and
 18 omissions caused consumer injury and harm to the public interests of protecting public health and the
 19 public's right to know about any harmful constituents in the Products.

20 136. Defendant's acts and omissions violate Nevada Deceptive Trade Practice Act, NEV.
 21 REV. STATUTES, Title 52, Chapter 598 *et seq.* which prohibits Defendant from making false statements
 22 about their Products and advertising the Products without the intent to sell them as advertised.

23 137. Defendants' acts and omissions violated Ohio's Consumer Sales Practices Act, OHIO
 24 REV. CODE ANN. § 1345.01, *et seq.* which prohibits sales practices that are deceptive, unfair, or
 25 unconscionable, and Ohio's Deceptive Trade Practices Act, OHIO REV. CODE ANN. § 4165 *et seq.*

26 138. Defendant's acts and omissions violated Pennsylvania's Unfair Trade Practices and
 27 Consumer Protection Law, 73 P.S. §§201-1 *et seq.* because Defendant: (1) caused the likelihood of
 28 confusion or of misunderstanding as to the source, sponsorship, approval, or certification of the

Products; (2) used deceptive representations about the Products; (3) represented the Products had characteristics, ingredients, or benefits, they did not; (3) represented the Products were not deteriorated or altered, when they were; (4) represented the Products were particular standard or quality when they are not; and (5) advertised the Products with the intent not to sell them as advertised.

139. Defendant's acts and omissions violated Rhode Island's Deceptive Trade Practices Act, R.I. GEN. LAWS § 6-13.1-5.2(B), *et seq.* because Defendant: (1) caused likelihood of confusion or of misunderstanding as to the source, sponsorship, approval, or certification of the Products; (2) used deceptive representations in connection with the Products; (3) represented the Products had sponsorship, approval, characteristics, ingredients, uses, benefits, they did not; (4) represented the Products were not deteriorated or altered, when they were; (5) represented the Products were of a particular standard, quality, or grade, when they were not; and (6) advertised the Products with the intent not to sell them as advertised.

140. Defendant's acts and omissions violated Washington's Consumer Protection Act, WASH. REV. CODE § 19.86.010, *et seq.*, which broadly prohibits Defendant from engaging in unfair methods of competition and unfair or deceptive acts or practices in the conduct of any trade or commerce.⁶⁶ Defendant's concealment of material health and safety information about the Products, which they knew or should have known, was injurious to the public interests of protecting public health and the public's right to know about any harmful constituents in the Products. Defendant's conduct caused harm to the Plaintiff, the Washington subclass members, and members of the public who bought the Products without knowing they degraded to benzene. Defendant's conduct has the capacity to cause harm to other persons who buy the Products.

141. Had Defendant been truthful in their advertising, labeling, and packaging of the Products and not omitted material health and safety information about benzene in and formed from the Products, Plaintiff, the Class, and Subclass members would not have bought the Products.

142. Defendant's acts and omissions and violations of the state consumer protection statutes

⁶⁶ Under § 19.86.090, Washington consumers harmed by such practices may recover actual damages, the costs of the suit, including reasonable attorney's fees, and the court may, in its discretion, increase the award of damages to an amount up to three times the actual damages sustained.

1 are ongoing and continuing to cause harm.

2 143. Plaintiff, on behalf of herself, and the Subclasses suffered an ascertainable economic
3 loss because of Defendant's misconduct because they bought the Products, they would not have
4 bought but for Defendant's misrepresentations.

5 144. Because of Defendant's misconduct, Plaintiff, on behalf of herself, and the Subclasses
6 seek recovery of their economic damages, attorneys' fees, punitive damages, and all other relief
7 allowable under the law. The damages sought are ascertainable, uniform and can be measured and
8 returned.

9 **E. BREACH OF EXPRESS WARRANTY, on Behalf of the Nationwide Class and on**
10 ***Behalf of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts,***
11 ***Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington***
State Subclasses

12 145. Plaintiff realleges and incorporates all other paragraphs in this Complaint and further
13 alleges:

14 146. Plaintiff brings this cause of action on behalf of herself, and all members of the National
15 Class and the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New
16 York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses, all of whom are
17 similarly situated consumers.

18 147. The Uniform Commercial Code § 2-313 provides that an affirmation of fact or promise
19 made by the seller to the buyer which relates to the goods and becomes part of the basis of the bargain
20 creates an express warranty that the goods shall conform to the promise. Defendant advertised and
21 sold the Products as safe, pure, of good quality, and only containing the listed ingredients.
22 Defendant's advertising, labels, containers, packaging, advertising, and online statements did not
23 mention benzene, leading consumers to believe the Products were safe for their ordinary use.
24 Defendant's affirmations were uniformly made to Plaintiff, the Class, and Subclass members by
25 Defendant in the Products' advertising, labeling, packaging, and online statements and were part of
26 the basis of the bargain between Defendant, the Plaintiff, the Class, and Subclass members.

27 148. Defendant's affirmations and promises are unlawful. When Defendant marketed,
28 distributed, and sold the Products, Defendant knew, or should have known, the Products degraded to

1 benzene under normal and expected use, handling, and storage conditions. Defendant knew, or should
 2 have known, the Products formed benzene and therefore did not conform to Defendant's express
 3 representations and warranties to consumers. Plaintiff, the Class, and Subclass members purchased the
 4 Products in reasonable reliance on Defendant's statements.

5 149. Because of Defendant's misconduct, Plaintiff, on behalf of herself, the Class and
 6 Subclass members seek recovery of their economic damages, attorneys' fees, punitive damages,
 7 restitution, and all other relief allowable by law, including an injunction to enjoin Defendant from
 8 continuing their fraudulent business practices. The damages sought are ascertainable, uniform to the
 9 Class and Subclasses and can be measured and returned to the Class and Subclass members.

10 **F. BREACH OF IMPLIED EXPRESS WARRANTY, on Behalf of the Nationwide**
 11 ***Class and on Behalf of the California, Hawaii, Illinois, Maryland, Massachusetts,***
 12 ***Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington***
Subclasses

13 150. Plaintiff realleges and incorporates all other paragraphs in this Complaint and further
 14 alleges:

15 151. Plaintiff brings this cause of action on behalf of herself, and all members of the National
 16 Class and the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New
 17 York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses, all of whom are
 18 similarly situated consumers.

19 152. Defendant, as sellers of the Products, also made implied warranties including
 20 warranting the Products were of the same quality and purity represented on the labels, in advertising,
 21 and on Defendant's websites, were fit for the ordinary purpose of the Products and conformed to the
 22 promises made on the containers, labels, advertising, and websites that all ingredients were listed, and
 23 all warnings given.

24 153. Defendant advertised their Products as safe, when they knew, or should have known,
 25 the Products degraded to benzene. Defendant did not list benzene as an ingredient or contaminant
 26 anywhere on the Products or advertising. The Products are not of the quality and purity represented by
 27 Defendant because the Products degrade to benzene under normal use, handling, and storage
 28 conditions.

154. Defendant did not tell Plaintiff or the Class or Subclass members the Products were not fit for their ordinary use because the Products, as advertised and sold by Defendant, degraded to benzene under normal and expected handling, use, and storage.

155. Defendant's affirmations that the Products were safe for use were uniformly made to the Plaintiff and the Class members in the Products' advertising, labeling, and packaging, and on Defendant's websites, which were part of the basis of the bargain.

156. Plaintiff, the Class, and Subclass members purchased the Products in reasonable reliance on Defendant's statements, affirmations, and omissions of material health and safety information.

157. Defendant's acts and omissions are ongoing and continuing to cause harm.

158. Because of Defendant's misconduct, Plaintiff, on behalf of herself, the Class and Subclass members, seek recovery of their actual damages, injunctive relief, attorneys' fees, punitive damages, and all other relief allowable under the law. The damages sought are uniform to the Class and Subclasses and the actual damages can be measured and returned to consumers who bought Defendant's Products.

G. UNJUST ENRICHMENT, on Behalf of the Nationwide Class and on Behalf of the California, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses

159. Plaintiff realleges and incorporates all other paragraphs in this Complaint and further alleges:

160. Plaintiff brings this cause of action on behalf of herself, and all members of the National Class and the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses, all of whom are similarly situated consumers.

161. Defendant has unjustly profited from their deceptive business practices and kept the profits from Plaintiff and the Class and Subclass members who purchased the Products.

162. Defendant requested and received a measurable economic benefit at the expense of Plaintiff, the Class, and Subclass members as payment for the Products. Defendant accepted the economic benefits from Plaintiff, the Class, and Subclass members knowing the economic benefit

1 received was based on deception and omission of material human health and safety information.

2 163. There is no utility in Defendant's misconduct and Defendant's enrichment from the
3 misconduct is unjust, inequitable, unconscionable, and against the strong public policy to protect
4 consumers against fraud.

5 164. Because of Defendant's misconduct, Plaintiff, on behalf of herself, the Class and
6 Subclass members, and the public seeks recovery of their actual damages, disgorgement of profits,
7 injunctive relief, attorneys' fees, punitive damages, and all other relief allowable under the law. The
8 damages sought are uniform to the Class and Subclasses and the actual damages can be measured and
9 returned to consumers who bought Defendant's Products.

10 **IX. PRAYER FOR RELIEF**

11 165. WHEREFORE, Plaintiff pray for judgment against Defendant:

12 166. That the Court determine this action may be maintained as a Class Action under Rule
13 23(a) and (b)(1), (2) and (3) of the Federal Rules of Civil Procedure;

- 14 a. That Defendant's misconduct be adjudged to have violated the state consumer
15 protection laws identified herein;
- 16 b. That injunctive and declaratory relief be awarded against Defendant, including but not
17 limited to an order prohibiting Defendant from engaging in the alleged misconduct;
- 18 c. That Defendant be ordered to disgorge profits and revenues derived from their course of
19 misconduct and that such unjust enrichment be restored to the class and or distributed
20 cy pres as the Court shall deem just and equitable;
- 21 d. That Plaintiff recover all compensatory damages and other damages sustained by
22 Plaintiff;
- 23 e. That Plaintiff recover punitive damages as allowed by law;
- 24 f. That Plaintiff recover all statutory damages as allowed by law;
- 25 g. That Plaintiff recover their attorneys' fees and all costs of suit;
- 26 h. That Plaintiff recover all Statutory pre-judgment and post-judgment interest on any
27 amounts; and
- 28 i. That all further relief as this Court may deem just and proper be granted.

X. DEMAND FOR JURY TRIAL

167. Demand is made for a jury trial.

Dated: March 8, 2024

WISNER BAUM LLP

By: /s/ R. Brent Wisner

R. Brent Wisner, Esq. (SBN: 276023)

rbwisner@wisnerbaum.com

11111 Santa Monica Blvd, #1750

Los Angeles, CA 90025

Telephone: (310) 207-3233

Facsimile: (310) 820-7444

Attorney for Plaintiff